Understanding how immune responses can help dissolve blood clots faster
Myeloid TLR4 epigenetic regulation and signaling in accelerating venous thrombus resolution
This study is looking at how certain immune cells help the body break down blood clots in the veins, with the goal of creating new treatments for deep venous thrombosis (DVT) that work differently than standard blood thinners, so patients can heal better and faster.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11026352 on NIH RePORTER |
What this research studies
This research focuses on the role of myeloid cells and their signaling pathways in the resolution of venous thrombus, which is a blood clot in the veins. The principal investigator, Dr. Andrea Obi, aims to develop new immune-based therapies that do not rely on traditional anticoagulants to treat deep venous thrombosis (DVT). By studying epigenetic modifications and immune responses, the research seeks to uncover mechanisms that can accelerate the natural resolution of blood clots. Patients may benefit from innovative treatments that enhance their body's ability to dissolve clots more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced deep venous thrombosis or are at risk for developing blood clots.
Not a fit: Patients who do not have a history of venous thromboembolism or related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve the resolution of blood clots, reducing complications associated with DVT.
How similar studies have performed: Other research has shown promise in using immune modulation to address thrombosis, indicating that this approach may lead to significant advancements.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Obi, Andrea Tara — University of Michigan at Ann Arbor
- Study coordinator: Obi, Andrea Tara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.